Nosological influenza systematization (ICD-10) G40.2 localized (focal) (partial) symptomatic epilep

The current veschestvoGabapentin * (Gabapentin *) Display all forms of production (3) of the capsule (3) Katena Capsules 300 mg, packaging contour cell 10, a pack of cardboard 5; kodEAN: 3850343013598; LSR-002168/10, from 2010-03-17 BELUPO dd (RespublikaHorvatiya) Katena Capsules 400 mg, packaging contour cell 10, a pack of cardboard 5; kodEAN: influenza 3850343027878; LSR-002168/10, 2010-03-17 from BELUPO dd (RespublikaHorvatiya) Katena Capsules 100 mg, package outline Valium 10 pack carton 2; kodEAN: influenza 3850343013772; LSR-002168/10, 2010-03-17 from BELUPO dd (RespublikaHorvatiya)
Last updated description proizvoditelem17.10.2012 Go: The pharmaceutical form and composition of drugs Pharmacodynamics Pharmacokinetics Indications Contraindications Pregnancy and breast-feeding Side acts Interaction Method of implementation and dose overdose Special instructions Product Manufacturer Conditions of supply of pharmacies Buy, Order, Prices influenza
Nosological influenza systematization (ICD-10) G40.2 localized (focal) (partial) symptomatic epilepsy and epileptic syndromes with all-encompassing partial convulsive seizures R52.2 Another constant pain
The pharmaceutical form and composition of the capsules 1 capsule. Active ingredient: gabapentin influenza 300 mg Other ingredients: lactose monohydrate, influenza maize starch, talc shell: titanium dioxide (E171), iron oxide yellow dye (E172) Gelatin Capsules influenza 1 capsule. Active ingredient: gabapentin 400 mg Other ingredients: lactose monohydrate, maize starch, talc shell: titanium dioxide (E171), iron oxide yellow dye (E172), iron oxide reddish dye (E172), gelatin description of the pharmaceutical form of 300 mg capsules: pure white crystalline powder in the capsule shell yellowish, size 1.
Pharmacological action deystvieFarmakologicheskoe - противоэпилептическое.Фармакодинамика gabapentin structurally similar to the neurotransmitter GABA but its mechanism of action differs from that of certain other drugs that interact with the GABA receptors, including valproate, barbiturates, benzodiazepines, GABA transaminase inhibitors, GABA uptake inhibitors, agonists of GABA and prodrugs of GABA: he does not possess the qualities of GABAergic and has no effect on GABA metabolism and seizure. Preliminary studies have shown that gabapentin is associated with α2-δ-subunit voltazhzavisimyh calcium channels and inhibits the flow of calcium ions, which plays an important role in the emergence of neuropathic pain. Other mechanisms involved in the action influenza of gabapentin for neuropathic pain are glutamatzavisimoy decrease neuronal death, increase the synthesis of GABA, inhibition of monoamine neurotransmitter release. Gabapentin in clinically significant concentrations does not bind to receptors or other drugs vserasprostranennyh neurotransmitters including sensors GABAA, GABAB, benzodiazepine, influenza glutamate, glycine, or N-methyl-D-aspartate. Unlike phenytoin and carbamazepine, gabapentin is not interact with sodium channels.
Bioavailability is not proportional to the dose of gabapentin, so by increasing the dose is reduced. After oral administration of gabapentin Cmax in plasma is reached after 2-3 hours absolute bioavailability of gabapentin capsules is approximately influenza 60%. The food, including with high content of fat, has no effect on pharmacokinetics. Excretion of gabapentin plasma is best described by a linear model.
Pharmacokinetics do not vary with repeated use; Css in plasma can be predicted on the basis of a single dose of the product. Gabapentin does not actually bound to plasma proteins (<3%) and has Vd 57,7 l.
Ground clearance of gabapentin plasma falls, pensioners and patients with impaired renal function. Elimination rate constant, plasma clearance and renal clearance are directly proportional to creatinine Cl. Gabapentin is removed from plasma by hemodialysis. In patients with impaired renal function and patients receiving hemodialysis healing, we recommend a dose adjustment (see "Method of implementation and administration"). The concentrations of gabapentin in the plasma of children aged 4 to 12 years are generally similar to those in adults.
monotherapy of partial seizures in epilepsy with and without secondary generalization in adults and her kids over the age of 12 years (the efficacy and safety of monotherapy in children under the age of 12 years have not been established);
as an additional tool in the treatment of partial seizures influenza in epilepsy with and without secondary generalization in adults and her children aged 3 years and over (safety and efficacy of adjunctive therapy with gabapentin in children at least 3 years of age have not been established).
Pregnancy and breast-feeding data on the safety and effectiveness of the implementation of the product in pregnancy, because the use of gabapentin in pregnancy we can